Darbepoetin alfa + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Darbepoetin alfa + Placebo
Darbepoetin alfa + Placebo is a phase 3 stage product being developed by Amgen for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT01362140. Target conditions include MDS.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01362140 | Phase 3 | Completed |
| NCT00858364 | Phase 3 | Terminated |
| NCT00436748 | Phase 3 | Terminated |
| NCT00364845 | Phase 3 | Terminated |
| NCT00358215 | Phase 3 | Completed |
| NCT00091858 | Phase 3 | Completed |
| NCT00110955 | Phase 3 | Completed |
| NCT03776032 | Phase 3 | Completed |
Competing Products
20 competing products in MDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 77 |
| KRN321 | Kyowa Kirin | Phase 2 | 52 |
| Azacitidine + Venetoclax | AbbVie | Phase 1 | 33 |
| venetoclax + azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Azacitidine + Placebo | AbbVie | Phase 3 | 77 |
| venetoclax + azacitidine +/- donor lymphocyte infusion | AbbVie | Phase 1/2 | 41 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Azacitidine and LDE255 | Novartis | Phase 1 | 33 |
| MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine) | Novartis | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| Azacitidine + Azacitidine plus Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox, Vitamin D and Azacitidine | Novartis | Phase 1/2 | 41 |
| LGH447 + LGH447 + midostaurin | Novartis | Phase 1 | 33 |
| Panobinostat | Novartis | Phase 1 | 33 |
| sabatolimab + azacitidine + venetoclax | Novartis | Phase 2 | 52 |
| LBH589 + Epoetin Alfa | Novartis | Phase 2 | 52 |
| Placebo + Romiplostim | Amgen | Phase 2 | 51 |
| Darbepoetin Alfa | Amgen | Phase 3 | 76 |